Search Orphan Drug Designations and Approvals
-
| Generic Name: | phenobarbital sodium | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Name: | Sezaby | ||||||||||||||||
| Date Designated: | 10/02/2019 | ||||||||||||||||
| Orphan Designation: | Treatment of neonatal seizures | ||||||||||||||||
| Orphan Designation Status: | Designated/Approved | ||||||||||||||||
| Sponsor: |
Sun Pharmaceutical Industries, Inc. 2 Independence Way Princeton, New Jersey 08540 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
| 1 | Generic Name: | phenobarbital sodium |
|---|---|---|
| Trade Name: | Sezaby | |
| Marketing Approval Date: | 11/17/2022 | |
| Approved Labeled Indication: | treatment of neonatal seizures in term and preterm infants | |
| Exclusivity End Date: | 11/17/2029 | |
| Exclusivity Protected Indication* : | treatment of neonatal seizures in term and preterm infants | |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







